ESTUDIO EN FASE II, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, DE GRUPOS PARALELOS, CONTROLADO POR PLACEBO, DE BÚSQUEDA DE DOSIS PARA EVALUAR LA SEGURIDAD Y EFICACIA DE 3 DOSIS ORALES DISTINTAS DE MT-1303 ADMINISTRADAS DURANTE UN PERIODO DE 24 SEMANAS A PA CIENTES CON ESCLEROSIS MÚLTIPLE REMITENTE-RECIDIVANTE.

An algorithm to predict intrathecal synthesis of IgG with high efficiency

Tortosa-Carreres, Jordi; (...); Casanova, Bonaventura

Meeting Abstract. 2023

Anti-CD20 monoclonal antibodies in primary progressive multiple sclerosis: a real-life comparative study of rituximab vs. ocrelizumab

Alcala, C.; (...); Casanova, B.

Meeting Abstract. 2021

Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer's Disease and Frontotemporal Dementia.

Álvarez-Sánchez L; (...); Cháfer-Pericás C

Article. 10.3390/ijms24021226. 2023

• 
• 
• PlumX Metrics

  

  • Citations
    • Citation Indexes: 16
  • Captures
    • Readers: 42
  • Mentions
    • Blog Mentions: 1
    • News Mentions: 2

  see details
• 19

  

Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.

Monreal, Enric; (...); Villar LM

Article. 10.1001/jamaneurol.2023.0010. 2023

• 
• 
• PlumX Metrics

  

  • Citations
    • Policy Citations: 3
    • Citation Indexes: 20
  • Captures
    • Readers: 50
  • Mentions
    • News Mentions: 1
  • Social Media
    • Shares, Likes & Comments: 48

  see details
• 24

  

Autologous hematopoietic stem cell transplantation in multiple sclerosis: updating outcomes in the Valencian cohort.

Boix Lago, A.; (...); Casanova Estruch, B.

Meeting Abstract. 2023

Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis.

Perez-Miralles, Francisco Carlos; (...); Casanova, Bonaventura

Article. 10.1002/brb3.2044. 2021

• 
• 
• PlumX Metrics

  

  • Citations
    • Citation Indexes: 6
  • Captures
    • Readers: 26

  see details
• 4

  

Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series.

Quintanilla-Bordás C; (...); Casanova B

Article. 10.3389/fneur.2022.897275. 2022

• 
• 
• PlumX Metrics

  

  • Citations
    • Citation Indexes: 14
  • Captures
    • Readers: 46
  • Mentions
    • News Mentions: 1
  • Social Media
    • Shares, Likes & Comments: 8

  see details
• 15

  

Cerebrospinal fluid kappa free light chains and IgM index for diagnosis and prognosis in multiple sclerosis

Gil-Perotin, S.; (...); Casanova, B.

Meeting Abstract. 2021

Cervical spinal cord T2 lesions independently predict early conversion to secondary progressive multiple sclerosis: a longitudinal 10-year study

Lacruz-Ballester, L.; (...); Casanova-Estruch, B.

Meeting Abstract. 2021

Circulating mirna signatures in PPMS

Martin, MMS; (...); Torrenta, LRI

Meeting Abstract. 2020

Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study

Oreja-Guevara, Celia; (...); Rio, Jordi

Article. 10.1016/j.msard.2024.105787. 2024

• 
• 
• 1

  

Clinical experiences with cannabinoids in spasticity management in multiple sclerosis

Lorente Fernández L; (...); Casanova-Estruch B

Article. 10.1016/j.nrl.2013.06.014. 2014

• 
• 
• 17

  

Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels

Quintanilla-Bordas, Carlos; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2024.1477335. 2024

Comparative Assessment of Simoa and Lumipulse for Measuring Serum Neurofilament Light Chain in Multiple Sclerosis Patients

Gasque-Rubio, Raquel; (...); Perez-Miralles, Francisco

Article. 10.1155/2024/1950913. 2024

Consensus guidelines for the timely detection and diagnosis of disease progression in multiple sclerosis patients

Oreja-Guevara, C; (...); Meca-Lallana, J

Meeting Abstract. 2020

Consensus on early detection of disease progression in patients with multiple sclerosis

Meca-Lallana, Jose E.; (...); Oreja-Guevara, Celia

Article. 10.3389/fneur.2022.931014. 2022

• 
• 
• 10

  

Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABA A receptor encephalitis.

Brändle SM; (...); Dornmair K

Article. 10.1073/pnas.1916337118. 2021

• 
• 
• 24

  

CSF chitinase 3-like-1 association with disability of primary progressive MS

Perez-Miralles, F; (...); Casanova, B

Article. 10.1212/NXI.0000000000000815. 2020

• 
• 
• 29

  

Cytokines profile in the cerebrospinal fluid in chronic relapsing inflammatory demyelinating diseases of the central nervous system

Simo-Castello, M.; (...); Coret, F.

Meeting Abstract. 2014

Characterization of the gait in patients with relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis measured by FeetMe (R) integrated sensor insole system: Results of the interim analysis

Izquierdo Ayuso, G.; (...); Casanova Estruch, B.

Meeting Abstract. 2021

Design and Validation of an Expanded Disability Status Scale Model in Multiple Sclerosis.

Barreiro-Gonzalez, Antonio; (...); Casanova, Bonaventura

Article. 10.1159/000519772. 2022

• 
• 8

  

DISCOVER STUDY, FIRST ANALYSIS SPECIFIC FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS BURDEN AND COST IN SPAIN: INTERIM ANALYSIS RESULTS

Oreja-Guevara, C; (...); Meca-Lallana, J

Meeting Abstract. 2020

Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.

Brieva, Luis; (...); Moral, Ester

Article. 10.1016/j.msard.2022.103805. 2022

• 
• 5

  

Does benign multiple sclerosis exist?

Verdini Martinez, Laura; (...); Casanova, Bonaventura

Meeting Abstract. 2023

Dynamic 18F-FDG PET to detect differences among patients with progressive and relapsing multiple sclerosis: a pilot study

Quintanilla Bordas, Carlos; (...); Casanova, Bonaventura

Meeting Abstract. 2023

Dyschromatopsia in multiple sclerosis reflects diffuse chronic neurodegeneration beyond anatomical landmarks.

Barreiro-González A; (...); Casanova B

Article. 10.1007/s13760-020-01516-x. 2020

• 
• 2

  

Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers

Alvarez-Sanchez, Lourdes; (...); Chafer-Pericas, Consuelo

Article. 10.3390/ijms241814151. 2023

• 
• 
• 2

  

Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study.

Meca-Lallana, J E; (...); Calles Hernandez, C

Article. 10.1016/j.nrleng.2021.06.006. 2023

• 
• 3

  

Early beginning of alemtuzumab: changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study

Meca-Lallana, J. E.; (...); Hernandez, C. Calles

Article. 10.1016/j.nrl.2021.06.007. 2024

• 
• 3

  

Economic impact and clinical profile of the secondary progressive multiple sclerosis (SPMS) patient: the DISCOVER study

Oreja-Guevara, C.; (...); Meca-Lallana, J. E.

Meeting Abstract. 2021

Economic impact of the secondary progressive multiple sclerosis in spain: interim analysis of the discover study

Oreja-Guevara, C; (...); Meca-Lallana, J

Meeting Abstract. 2020

Eculizumab for a catastrophic relapse in NMOSD: case report.

Gorriz, David; (...); Casanova, Bonaventura

Article. 10.1007/s10072-023-06971-x. 2023

• 
• 6

  

Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.

Meca-Lallana JE; (...); Llarena C

Article. 10.1007/s40120-023-00557-7. 2023

• 
• 
• 1

  

Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.

Alcala, Carmen; (...); Casanova, Bonaventura

Article. 10.1007/s00415-022-10989-0. 2022

• 
• 14

  

Elevation of serum neurofilament light-chain levels disclose possible occult progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient receiving ozanimod: a case report.

Quintanilla-Bordás C; (...); Pérez-Miralles FC

Case Reports. 10.3389/fimmu.2024.1465678. 2024

• 
• 1

  

Escalation vs. Early Intense Therapy in Multiple Sclerosis.

Casanova, Bonaventura, Quintanilla-Bordas, Carlos, Gascon, Francisco

Article. 10.3390/jpm12010119. 2022

• 
• 
• 32

  

Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.jneuroim.2024.578428. 2024

High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis.

Castillo-Villalba, Jessica; (...); Casanova, Bonaventura

Article. 10.3389/fimmu.2022.827738. 2022

• 
• 
• 12

  

Improvements in Quality of Life of Patients with Multiple Sclerosis receiving Alemtuzumab in Clinical Practice: LEMVIDA study

Meca Lallana, Jose; (...); Forner, Mireia

Meeting Abstract. 10.1212/WNL.0000000000202381. 2023

Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.

Meca-Lallana, Jose Eustasio; (...); Toledo, Baldo

Article. 10.1186/s41687-024-00822-9. 2024

Improving the efficiency of free kappa light chains as diagnostic biomarker of Multiple Sclerosis by using a novel algorithm.

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.msard.2023.104997. 2023

• 
• 2

  

Long-term efficacy of alemtuzumab in multiple sclerosis: a real word multicenter Spanish experience

Rubio Alcantud, Almudena; (...); Casanova, Bonaventura

Meeting Abstract. 2023

Magnetic resonance imaging and optical coherence tomography correlations in multiple sclerosis beyond anatomical landmarks.

Barreiro-González A; (...); Casanova B

Article. 10.1016/j.jns.2020.117180. 2020

• 
• 7

  

Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview

Garcia-Foncillas, J; (...); Gomez, MVP

Review. 10.1007/s40291-021-00544-4. 2021

• 
• 15

  

miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.

Munoz-San Martin, Maria; (...); Ramio-Torrenta, Lluis

Article. 10.1212/NXI.0000000000200069. 2023

• 
• 
• 10

  

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.

Toboso I; (...); Villar LM

Article. 10.3389/fneur.2020.579438. 2020

• 
• 
• 13

  

NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.

Alcala, C.; (...); Casanova, B.

Article. 10.1007/s00415-021-10926-7. 2022

• 
• 4

  

Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis.

Alcala Vicente, Carmen; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2022.991596. 2022

• 
• 
• 2

  

Oligoclonal M bands distinguish two MS populations based on neurofilament light chain levels in patients without inflammatory activity

Castillo, J.; (...); Casanova, B.

Meeting Abstract. 2022

Oligoclonal M bands unveil occult inflammation in multiple sclerosis.

Casanova B; (...); Pérez-Miralles F

Article. 10.1016/j.msard.2022.104118. 2022

• 
• 6

  

Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies.

Coret F; (...); Casanova B

Article. 10.1177/2055217318783347. 2018

• 
• 
• 33

  

Perception of stigma in people with neuromyelitis optica spectrum disorders (PERSPECTIVES-NMO Study)

Lallana, Jose Meca; (...); Maurino, Jorge

Meeting Abstract. 2021

Potential Biomarkers Associated with Multiple Sclerosis Pathology.

Mathur, Deepali; (...); Casanova, Bonaventura

Article. 10.3390/ijms221910323. 2021

• 
• 
• 19

  

Potential Role of CHI3L1+ Astrocytes in Progression in MS.

Cubas-Núñez L; (...); Casanova B

Article. 10.1212/NXI.0000000000000972. 2021

• 
• 
• 35

  

Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.msard.2024.105734. 2024

• 
• 3

  

Quantifying the patient's perspective in neuromyelitis optica spectrum disorders: design of a multicenter, non-interventional study

Meca-Lallana, J; (...); Maurino, J

Meeting Abstract. 2020

Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.

Ramo-Tello, Cristina; (...); Rovira À

Article. 10.3390/jpm12010006. 2021

• 
• 
• 18

  

Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease

Alcala, C; (...); Casanova, B

Editorial Material. 10.1016/j.msard.2018.12.005. 2019

• 
• 19

  

Renal function's impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis.

Tortosa-Carreres, Jordi; (...); Perez-Miralles, Francisco

Article. 10.1007/s10072-024-07772-6. 2024

• 2

  

Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.

Monreal E; (...); Villar LM

Article. 10.1093/brain/awae260. 2024

• 
• 7

  

Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels at Disease Onset for Prediction of the Risk of Disability Worsening in Patients with Multiple Sclerosis

Monreal, Enric; (...); Villar Guimerans, Luisa Maria

Meeting Abstract. 2023

Serum neurofilament light chain and glial fibrillary acidic protein levels at disease onset unveil immunological pathways of disability acquisition in multiple sclerosis

Monreal, Enric; (...); Villar Guimerans, Luisa Maria

Meeting Abstract. 2024

Serum Neurofilament Light Chain is a surrogate marker of NEDA-3 in Multiple Sclerosis

Gascon Gimenez, Francisco Guillermo; (...); Casanova, Bonaventura

Meeting Abstract. 2023

Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study).

Pérez-Miralles F; (...); Casanova B

Article. 10.1016/j.msard.2021.102860. 2021

• 
• 17

  

Treatment of multiple sclerosis with Rituximab: a multicenter Spanish experience

Alcala, C.; (...); Casanova, B.

Meeting Abstract. 2021

Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience.

Gascon-Gimenez, Francisco; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2023.1060696. 2023

• 
• 
• 1

  

Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain.

Landete, Lamberto; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2021.727586. 2021

• 
• 
• 7